Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Influenza in Humans
- Main trialPhase 1
- “This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy volunteers.”In the company’s words, NCT02888327 on ClinicalTrials.gov
Other drugs for Influenza in Humans
- MRNA-1018-H5Moderna · Phase 3
- Baloxavir MarboxilRoche · Phase 3
- BRC-201Boryung Biopharma Co., Ltd. · Phase 3
- Dipyrone monohydrateBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- CD388Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 3
- MRNA Seasonal Flu vaccineGSK · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 30 May 2017 | A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026